BioSpace News Archive

Allara today announced $10 million in Series A funding led by GV (Google Ventures), with participation from Great Oaks Venture Capital, Humbition, Vanterra, Gaingels, and individual investors, including Tom Lee (One Medical) and Maggie Sellers.

Celcuity Inc. announced today that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50 million.

Continuing on its commitment to advance the field of reproductive medicine, Inception Fertility™ (Inception), the largest provider of comprehensive fertility products and services in North America, proudly announces its participation at 2023 ASRM Scientific Congress, taking place October 14-18, 2023, in New Orleans, Louisiana.

ulrich medical USA, the pioneer in expandable corpectomy devices and a market leader in spine technology, today announced at the North American Spine Society 38th Annual Meeting, the full U.S. commercial launch of the Momentum MIS Posterior Spinal Fixation System.

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Y-mAbs Therapeutics, Inc. announced that its Board of Directors has appointed Michael Rossi as President and Chief Executive Officer and a member of the Board of Directors with an expected start date of November 6, 2023.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology (ASCO) small cell lung cancer (SCLC) guidelines for patients with untreated or previously treated extensive-stage small cell lung cancer (ES-SCLC) who are undergoing treatment with chemotherapy or chemoimmunotherapy.

Adial Pharmaceuticals, Inc. announced that it has been awarded the 2023 Best Practices Technology Innovation Leadership Award in the North American precision medicine for addiction disorders industry by Frost & Sullivan, an American business consulting firm that offers market research and analysis, growth strategy consulting, and corporate training.

Baudax Bio, Inc. today announced that following recent shareholder approval of corporate actions related to its June 29 2023 acquisition of TeraImmune, the Company is now poised to initiate clinical development of TI-168, the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.